Drugmaker GSK said on Tuesday that its linerixibat candidate had shown "positive" Phase III results in cholestatic pruritus ...
UK pharma major GSK today announced positive headline results of GLISTEN, the ongoing global Phase III clinical trial ...
GSK's phase 3 GLISTEN trial demonstrated linerixibat's potential to treat relentless itch in PBC patients, meeting its ...
GSK (GSK) announced headline results of GLISTEN, the ongoing global phase III clinical trial evaluating linerixibat, an investigational targeted inhibitor of the ileal bile acid transporter, IBAT, in ...
A phase 3 trial of GSK’s linerixibat in a liver disease has hit its primary endpoint, keeping the drugmaker on track to ...
GSK announces positive results from GLISTEN phase III trial of linerixibat in adults with cholestatic pruritus (relentless itch) associated with PBC: London, UK Wednesday, Novembe ...
GSK (NYSE:GSK) said a Phase 3 study of its drug linerixibat in the treatment of relentless itching in patients with primary ...
Interim results from the ongoing GLISTEN trial of linerixibat, GSK's targeted inhibitor of the ileal bile acid transporter ...
The London-based pharmaceutical company said that in cholestatic pruritus, also known as relentless itch, in primary biliary cholangitis, an autoimmune disease known as PBC, linerixibat showed a ...
British drugmaker GSK said on Tuesday its experimental therapy, linerixibat, met its main goal in a late-stage trial to treat ...
Medpage Today on MSN1d
'Stop RFK War Room'; Trump Overhauling Medicaid? Why Assaults at Hospitals RoseSome healthcare advocacy groups launched a "Stop RFK War Room" to fight Robert F. Kennedy Jr.'s nomination for HHS Secretary.
The GSK share price has been in a strong freefall after peaking at 1,785p in September. Most recently, the GSK stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback